Transforming medical devices for improved patient outcomes

DESSOLVE China Three-Year Angiographic Sub-study

DESSOLVE China will also include an angiographic sub-study evaluation of 100 patients (50 MiStent SES, 50 TIVOLI) at baseline, nine and 36 months post-treatment to evaluate and compare for advantages of MiStent SES in the progression of late lumen loss and other angiographic measures over time.

Principal Investigator:
Prof. Yaling Han, General Hospital, Shenyang Military Region, Shenyang, China

More information on the DESSOLVE C trial can be found here.